REGAL is a Phase 3 randomized study testing GPS in AML patients who reached complete remission after a second round of rescue ...

The 2024-25 Sustainability Report reflects the company’s long-term view-one that places science, responsibility, and ...

Salesforce (NYSE: CRM), the world’s #1 AI CRM, announced today that Novartis (NYSE: NVS), a leading global innovative ...

For a stock that had been struggling for significance for much of the past year, this dramatic shift was not merely a rally — ...

Agentforce Life Sciences platform continues to gain momentum across the healthcare industry. Recently, Novartis ($NVS) ...

Through the first three quarters of 2025, M&A activity overtook the entire 2024 total, according to Endpoints News. Editor and founder John Carroll wrote in October this might be the best time in 15 ...

Wave Life Sciences Ltd is a pioneering force in genetic medicine, focusing on creating innovative treatments for serious ...

Discover why Wave Life Sciences Ltd. is a high-risk, high-reward biotech with unique RNA therapies for AATD, obesity, and ...

We have an emerging new entrant in the increasingly crowded weight loss drug space.

Life Sciences ventures face high levels of scientific, clinical and commercial pathway uncertainty, and these uncertainties present many opportunities for entrepreneurial innovation. This course is ...

The developer behind Philadelphia's largest life sciences building says the market needs patience after venture capital ...

Actively moving up the value chain toward drug discovery, development and digital therapeutics is key to sustaining the State ...